Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIM NASDAQ:LENZ NYSE:RCUS NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ALENZLENZ Therapeutics$38.63+1.1%$33.95$16.53▼$41.70$1.09B0.42788,388 shs222,755 shsRCUSArcus Biosciences$10.60-0.1%$9.42$6.50▼$18.98$1.13B0.89759,613 shs548,275 shsZYMEZymeworks$14.81-0.2%$13.45$9.03▼$17.70$1.11B1.26526,977 shs314,217 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%-0.18%LENZLENZ Therapeutics+1.13%-3.42%+25.59%+31.89%+74.80%RCUSArcus Biosciences-0.19%+0.82%+12.59%+17.98%-38.62%ZYMEZymeworks-0.20%-1.92%+14.45%+26.91%+30.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/ALENZLENZ Therapeutics1.7051 of 5 stars3.51.00.00.03.30.80.0RCUSArcus Biosciences2.3703 of 5 stars3.43.00.00.03.11.70.0ZYMEZymeworks2.2822 of 5 stars3.50.00.00.03.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 0.00N/AN/AN/ALENZLENZ Therapeutics 3.00Buy$49.6028.40% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1499.56% UpsideZYMEZymeworks 2.90Moderate Buy$21.4344.69% UpsideCurrent Analyst Ratings BreakdownLatest ALIM, LENZ, ZYME, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $22.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $25.007/31/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $49.007/31/2025LENZLENZ TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.007/28/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $48.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$13.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30LENZLENZ Therapeutics$5M220.36N/AN/A$7.24 per share5.34RCUSArcus Biosciences$258M4.37N/AN/A$5.16 per share2.05ZYMEZymeworks$122.87M9.06N/AN/A$6.63 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/ALENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)ZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest ALIM, LENZ, ZYME, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62LENZLENZ TherapeuticsN/A20.5420.54RCUSArcus Biosciences0.184.504.50ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%LENZLENZ Therapeutics54.32%RCUSArcus Biosciences92.89%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%LENZLENZ Therapeutics6.90%RCUSArcus Biosciences9.60%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/ARCUSArcus Biosciences500106.43 million96.21 millionOptionableZYMEZymeworks46075.17 million67.56 millionOptionableALIM, LENZ, ZYME, and RCUS HeadlinesRecent News About These CompaniesWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30 at 5:00 AM | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30 at 4:33 AM | marketbeat.comZymeworks Reports Q2 Results and FDA ClearanceAugust 19, 2025 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesAugust 19, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital LtdAugust 17, 2025 | marketbeat.comZymeworks Earnings Call: Revenue Surge and Strategic GainsAugust 13, 2025 | msn.comZymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAugust 12, 2025 | zacks.comCitigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00August 12, 2025 | marketbeat.comQ1 Earnings Estimate for Zymeworks Issued By Lifesci CapitalAugust 12, 2025 | marketbeat.comZymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. LandryAugust 11, 2025 | finanznachrichten.deZymeworks Strengthens Leadership with New Board AppointmentsAugust 11, 2025 | tipranks.comZymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of DirectorsAugust 11, 2025 | quiverquant.comQZymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. LandryAugust 11, 2025 | financialpost.comFZymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. LandryAugust 11, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsAugust 11, 2025 | marketbeat.comEarnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsAugust 10, 2025 | finance.yahoo.comZymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPSAugust 9, 2025 | marketbeat.comZymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progressionAugust 8, 2025 | msn.comZymeworks Inc. (ZYME) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comZymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue EstimatesAugust 7, 2025 | zacks.comZymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALIM, LENZ, ZYME, and RCUS Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.LENZ Therapeutics NASDAQ:LENZ$38.63 +0.43 (+1.13%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$38.62 -0.01 (-0.03%) As of 08/29/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Arcus Biosciences NYSE:RCUS$10.60 -0.02 (-0.14%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$10.60 +0.00 (+0.04%) As of 08/29/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Zymeworks NYSE:ZYME$14.81 -0.03 (-0.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.81 0.00 (0.00%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
